At Rambilli Industrial Park in the Andhra Pradesh district of Anakapalli, Blue Jet Healthcare Ltd. is scheduled to begin construction on a Rs 2,300 crore greenfield pharmaceutical manufacturing facility. The project represents a significant increase in India’s capacity to provide contract development and manufacturing organization services as well as speciality chemicals.
The 102-acre complex will produce versatile chemical products, high-intensity sweeteners, and contrast media intermediates. The facility is anticipated to be operational by FY2028–2029 and will be developed in phases. It is anticipated to improve the industrial environment in the Visakhapatnam region by creating about 1,750 direct jobs and 250 indirect jobs once it is put into service.
Expanding CDMO capabilities and specialised intermediates:
Originally established as Jet Chemicals Pvt Ltd in 1968, Blue Jet Healthcare has developed into a comprehensive CDMO that supplies cutting-edge pharmaceutical intermediates and APIs to the US, Europe, and India. The company was one of the first to make saccharin in India and is a major player in contrast media intermediates.
It has developed competence in scale-up, process chemistry, and production systems that comply with regulations over the years. The Rambilli investment is in line with the business’s plan to broaden its worldwide CDMO presence and cater to multinational pharmaceutical customers who want to diversify their supply chains outside national borders.
Pay attention to ESG-compliant pharmaceutical production:
The new facility will have an advanced effluent treatment plant with marine discharge connectivity and zero liquid discharge technology. The system is intended to recover 90 to 95 percent of wastewater while reducing energy use by around 70%. This strategy backs stricter environmental compliance standards and ESG benchmarks for global pharmaceutical supply chains.
Under the direction of Managing Director Shiven Akshay Arora and Executive Chairman Akshay Bansarilal Arora, the company’s growth demonstrates a sustained dedication to sustainable pharmaceutical manufacture and high-value speciality intermediates.
The project strengthens Rambilli Industrial Park’s standing as a center for the production of pharmaceuticals and speciality chemicals along India’s eastern coast. As India moves up the global pharmaceutical value chain, it indicates sustained investment momentum in complex intermediates for the sector as a whole.
